Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease [Phase 2, Phase 3]

View source ↗

Summary

A safety and efficacy study of CTX001 in subjects with severe Sickle Cell Disease has completed Phase 2 and Phase 3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Diseases
• Hemoglobinopathies
• Sickle Cell Disease

Drugs mentioned

• CTX001

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Sickle Cell Disease, Hematological Diseases | Phase 2, Phase 3 | Status: COMPLETED